Clinical Effect of Different Doses of Mifepristone in Treatment of Premenopausal Hysteromyoma and Influence of the Expression of Vascular Endothelial Growth factor and Its Receptor

HE Li-qiong; WANG Qun; JIA Shu-yun; LIU Qin

doi:10.3969/j.issn.1002-3429.2016.02.031

Abstract：Objective To discuss the clinical effect of different doses of Mifepristone in treatment of premenopausal hysteromyoma and influence of the expression of vascular endothelial growth factor ( VEGF) and its receptor vascular endothe-lial growth factor receptor (VEGFR) 1 and VEGFR2. Methods 80 cases of confirmed premenopausal hysteromyoma in the department of obstetrics and gynecology of Central Hospital of Panzhihua during October 2011 and December 2012 were select-ed as the research objects, and according to random number table method and registration order, divided into the high dose group and low dose group ( n=40 in each group) . High dose group had 25 mg daily of oral Mifepristone, low dose group was given 12. 5 mg daily of oral Mifepristone. Therapeutic effect, concentration of VEGF and its receptor VEGFR1, VEGFR2 in peripheral blood before and after treatment and the safety rates were compared between the two groups. Results During the therapeutic process, 1 case of the high dose group fell off, and 2 cases of the low dose group fell off. After two courses of treat-ment, the effective rate of high dose group was 84. 62%, while the effective rate in low dose group was 84. 21%, and there was no statistical significance between the two groups (P>0. 05). After two courses of treatment, hysteromyoma volume of the two groups shrank significantly compared with that before treatment, while concentration of VEGF and its receptor VEGFR1, VEGFR2 in the peripheral blood were less than that before treatment, and the differences were statistically significant ( P<0. 05), but the differences between the two groups before and after 2 courses of treatment in the hysteromyoma volume, pe-ripheral blood VEGF and its receptor VEGFR1, VEGFR2 concentration were of no statistical significance (P>0. 05). After two courses of treatment, incidence rate of adverse reactions in the high dose group was 17. 95%, 5. 26% in the low dose group, and difference was of statistical significance (P<0. 05). Conclusion Both low dose and high dose Mifepristone can inhibit the expression of peripheral blood VEGF and its receptors VEGFR1, VEGFR2 in the patients with menopausal hystero-myoma, which can gradually shrink the tumors volume and improve the effect of clinical symptoms. But low dose Mifepristone has low incidence rate of adverse reaction, better safety and lower expense of medication.